Bradley Foster & Sargent Inc. CT reduced its holdings in Zoetis Inc (NYSE:ZTS) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 291,436 shares of the company’s stock after selling 2,255 shares during the quarter. Bradley Foster & Sargent Inc. CT owned about 0.06% of Zoetis worth $20,995,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its position in Zoetis by 231,590.8% in the fourth quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock worth $152,557,000 after purchasing an additional 2,116,740 shares during the last quarter. Acadian Asset Management LLC boosted its position in Zoetis by 111.3% in the fourth quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock worth $123,143,000 after purchasing an additional 900,261 shares during the last quarter. Victory Capital Management Inc. boosted its position in Zoetis by 292.2% in the fourth quarter. Victory Capital Management Inc. now owns 1,063,051 shares of the company’s stock worth $76,583,000 after purchasing an additional 792,000 shares during the last quarter. Milestone Resources Group Ltd purchased a new position in Zoetis in the fourth quarter worth $40,294,000. Finally, Public Employees Retirement Association of Colorado boosted its position in Zoetis by 41.6% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 1,207,018 shares of the company’s stock worth $86,954,000 after purchasing an additional 354,786 shares during the last quarter. Hedge funds and other institutional investors own 93.72% of the company’s stock.
Zoetis Inc (NYSE ZTS) opened at $78.71 on Thursday. Zoetis Inc has a 52-week low of $52.00 and a 52-week high of $80.60. The stock has a market capitalization of $35,688.99, a P/E ratio of 39.19, a PEG ratio of 1.62 and a beta of 1.07. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be given a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio (DPR) is presently 26.32%.
A number of research firms recently issued reports on ZTS. BMO Capital Markets set a $65.00 price objective on Zoetis and gave the company a “hold” rating in a research note on Wednesday, October 25th. Zacks Investment Research lowered Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price on the stock. in a research note on Saturday, January 13th. Cantor Fitzgerald restated a “buy” rating and issued a $75.00 target price on shares of Zoetis in a research note on Tuesday, October 24th. Citigroup upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price objective for the company in a report on Thursday, January 4th. Finally, Cowen set a $80.00 price objective on Zoetis and gave the stock a “buy” rating in a report on Friday, November 17th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. Zoetis has a consensus rating of “Buy” and an average price target of $73.72.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.